Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Rokkas
Theodore
T
Sechopoulos
Panos
P
Robotis
John
J
Pistiolas
Dimitris
D
D000658:Amoxicillin / Q000009:adverse effects / Q000627:therapeutic use; D000667:Ampicillin / Q000009:adverse effects / Q000627:therapeutic use; D000863:Antacids / Q000009:adverse effects / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D001729:Bismuth / Q000009:adverse effects / Q000627:therapeutic use; D001944:Breath Tests; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D064704:Levofloxacin; D008795:Metronidazole / Q000009:adverse effects / Q000627:therapeutic use; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D009853:Omeprazole / Q000009:adverse effects / Q000627:therapeutic use; D011500:Protein Synthesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D013752:Tetracycline / Q000009:adverse effects / Q000627:therapeutic use; D017211:Treatment Failure
D000863:Antacids; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D011500:Protein Synthesis Inhibitors; D008795:Metronidazole; D064704:Levofloxacin; D000667:Ampicillin; D000658:Amoxicillin; D015242:Ofloxacin; D013752:Tetracycline; D017291:Clarithromycin; D009853:Omeprazole; D001729:Bismuth